Absci has partnered with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.

AMD will also make a USD 20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery.

The strategic partnership supports Absci’s mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs, and faster innovation cycles.

Absci and AMD will showcase the exceptional performance of AMD’s Instinct accelerators in addressing complex biological applications, including Absci’s proprietary IgDesign1 model, the first in vitro validated inverse folding model for antibody design.

"At Absci, we are always looking for ways to push the boundaries of what’s possible in drug discovery. This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available. AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery," said Sean McClain, Founder & CEO of Absci.

“We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed,” said Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD.

“Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads, “added Papermaster.